OncoSec Announces Presentations at Upcoming Investment and Scientific Conferences

SAN DIEGO, Sept. 6, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members of its leadership team will be presenting at several events in September, including:

• Rodman & Renshaw 18^th Annual Global Investment Conference
• Johnson & Johnson Innovation + JLABS Science 1^st Speaking Series
• Phacilitate Cell & Gene Therapy Europe 2017
• 2^nd World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies

Rodman & Renshaw 18^th Annual Global Investment Conference 
Punit Dhillon, OncoSec's Chief Executive Officer, will present a corporate overview at the Rodman & Renshaw 18^th Annual Global Investment Conference on September 11^th at 10:25 AM ET at The Lotte New York Palace Hotel in New York City.

Mr. Dhillon will be available to participate in one-on-one meetings with investors who are registered to attend the conference.  If you are an institutional investor, and would like to attend the Company's presentation or schedule a meeting, please click on the following link: www.rodmanevents.com.  

To view to the live webcast, please access the following link at the time of the presentation: http://wsw.com/webcast/rrshq27/oncs/. An archived version of the webcast will be available for 90 days on OncoSec's website: www.oncosec.com.

Johnson & Johnson Innovation + JLABS Science 1^st Speaking Series
Tu Diep, OncoSec's Vice President of Operations, will participate in a panel discussion entitled: "Designing Nucleic Acid Medicines" at the Johnson & Johnson Innovation + JLABS Science 1^st Speaking Series on September 13^th at 3:30 PM PT at the JLABS in San Diego, CA. For more information, please visit: www.jlabs.jnjinnovation.com/events/coming.

Phacilitate Cell & Gene Therapy Europe 2017
Mr. Diep will also participate in a panel discussion entitled: " Non-Viral Delivery Platforms – Does the Latest Data Support Widespread Ex Vivo and In Vivo Gene Therapy Application? " at the Phacilitate Cell & Gene Therapy Europe 2017 on September 21 at 11:30 AM CSET at the Maritim Proarte Hotel in Berlin, Germany. For more information, please visit: www.cgteurope.com.

2^nd World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies
Shawna Shirley, OncoSec's Senior Scientist, will present a poster entitled: "Intratumoral Electroporation of Plasmid IL-12 Using Modified Parameters and an Optimized DNA Plasmid Increases Immunogenicity in Untreated Lesions in Mice" at the 2^nd World Congress on Electroporation and Pulsed Electric Fields on September 25 at 2:00 PM ET at the Hilton Norfolk The Main in Norfolk, VA.

Adil Daud, MD, Chief Clinical Strategist at OncoSec and Professor of Medicine at the University of California, San Francisco, will also present a lecture during the "Electroporation Technologies for the Treatment of Cancer" session on September 25 at 11:10 AM PT entitled: "Local and Systemic Immunotherapy by Electroporation [OR-16]."

Alain Algazi, PhD, member of OncoSec's Clinical Advisory Board and Professor of Medicine at the University of California, San Francisco, will present a plenary lecture on September 27 at 8:30 AM ET entitled: "A Phase II Clinical Trial of Intratumoral Plasmid IL-12 with Electroporation in Combination with Pembrolizumab."

For more information, please visit: https://wc2017.electroporation.net/.

About OncoSec Medical Incorporated:
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for several indications, including metastatic melanoma, and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.

CONTACT:

Investor Relations  
OncoSec Medical Incorporated 
855-662-6732 
[email protected]

Media Relations  
OncoSec Medical Incorporated 
855-662-6732 
[email protected]

SOURCE OncoSec Medical Incorporated

Related Links

http://www.oncosec.com